Interim Report 2026
Filed with HKEX · Stock code 690 · · 78 pages · English
2 Corporate Information 4 Key Financial Highlights 33 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 35 Condensed Consolidated Statement of Financial Position 37 Condensed Consolidated Statement of Cash Flows 38 Condensed Consolidated Statement of Changes in Equity 40 Notes to the Condensed Consolidated Financial Statements 60 Other Information CORPORATE INFORMAT
Uni Bio Science Group, Ltd. on 6ix
Earlier from Uni Bio Science
- Uni Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches 肌顏態®: Pioneering Entry into the High Growth Medical Aesthetics Market
- Uni Bio Science Announces 2022 Annual Results，Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New Drug Innovations and Strategic R&D Partnerships
- Interim Report 2022
- Uni Bio Science opens Hong Kong research centre,Future R&D focus in four major businesses
- 2021 Annual Results—Achieved Record-High Turnover and EGF Products Recorded Strong Rebound Successful Expansion Into Ophthalmology and Other Potential Therapeutic Areas
Later from Uni Bio Science
- Notification letter and request form
- Notification letter and reply form
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Follow Uni Bio Science into a list and get an email when it puts out news.
Follow Uni Bio Science